সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - aciklovir - tablett - 800 mg - aciklovir 800 mg aktiv substans - aciklovir

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

towa pharmaceutical europe s.l. - duloxetinhydroklorid - enterokapsel, hård - 30 mg - natriumlaurilsulfat hjälpämne; duloxetinhydroklorid 33,678 mg aktiv substans; sackaros hjälpämne; sockersfärer hjälpämne - duloxetin

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

towa pharmaceutical europe s.l. - duloxetinhydroklorid - enterokapsel, hård - 60 mg - sackaros hjälpämne; duloxetinhydroklorid 67,356 mg aktiv substans; sockersfärer hjälpämne; natriumlaurilsulfat hjälpämne - duloxetin

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

bioprojet europe ltd - racekadotril - granulat till oral suspension - 10 mg - sackaros hjälpämne; racekadotril 10 mg aktiv substans - racekadotril

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

bioprojet europe ltd - racekadotril - kapsel, hård - 100 mg - racekadotril 100 mg aktiv substans; laktosmonohydrat hjälpämne - racekadotril

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

bioprojet europe ltd - racekadotril - granulat till oral suspension - 30 mg - sackaros hjälpämne; racekadotril 30 mg aktiv substans - racekadotril

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - sertralinhydroklorid - filmdragerad tablett - 50 mg - sertralinhydroklorid 55,96 mg aktiv substans - sertralin

ইউরোপীয় ইউনিয়ন - সুইডিশ - EMA (European Medicines Agency)

pfizer europe ma eeig  - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - immunstimulatorer, - filgrastim är indicerad för att reducera durationen av neutropeni och incidensen av febril neutropeni hos patienter som behandlats med etablerad cytotoxisk kemoterapi för malignitet (med undantag för kronisk myeloisk leukemi och myelodysplastiska syndrom) och för reduktion av durationen av neutropeni hos patienter som genomgår myeloablativ terapi följt av benmärgstransplantation anses vara ökad risk för förlängd svår neutropeni. säkerheten och effekten av filgrastim är lika hos vuxna och barn som får cytotoxisk kemoterapi. filgrastim är indicerat för mobilisering av perifera blod förstadier (pbpcs). i patienter, barn och vuxna, med svår kongenital, cyklisk eller idiopatisk neutropeni med ett absolut antal neutrofila granulocyter (anc) på ≤0. 5 x 109/l och en historia av allvarliga eller återkommande infektioner, långsiktig förvaltning av filgrastim är indicerat för att öka antalet neutrofila granulocyter och minska förekomsten och varaktigheten av infektioner-relaterade evenemang. filgrastim är indicerat för behandling av ihållande neutropeni (anc ≤1. 0 x 109 / l) hos patienter med avancerad hiv-infektion för att minska risken för bakterieinfektioner när andra alternativ för att hantera neutropeni är olämpliga.

ইউরোপীয় ইউনিয়ন - সুইডিশ - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunsuppressiva - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. behandling av svår, aktiv och progredierande reumatoid artrit hos vuxna som inte tidigare behandlats med metotrexat. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita minskar graden av progression av ledskador mätt med röntgen och förbättrar fysisk funktion, när det ges i kombination med metotrexat. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita kan ges som monoterapi vid intolerans mot metotrexat eller när fortsatt behandling med metotrexat är olämplig (för effekt i monoterapi se avsnitt 5. adalimumab har inte studerats hos patienter yngre än 2 år. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita minskar graden av progression av perifer ledskada mätt med röntgen hos patienter med polyartikulär symmetrisk subtyper av sjukdomen (se avsnitt 5. 1) och förbättrar fysisk funktion. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 och 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

cipla europe nv - karboplatin - koncentrat till infusionsvätska, lösning - 10 mg/ml - karboplatin 10 mg aktiv substans